GOLDA TROMPETA: Open Payments
NPI 1043927387 · CHESTERFIELD, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,598 in 86 payments from 14 companies in 2025. Trend: 2023 $1,274 · 2024 $2,268 · 2025 $1,598
Food & beverage: $1,598
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 17 | $440 |
| Otsuka America Pharmaceutical, Inc. | 13 | $227 |
| Teva Pharmaceuticals USA, Inc. | 15 | $157 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $156 |
| Vanda Pharmaceuticals Inc. | 5 | $147 |
| Neurocrine BioSciences, Inc. | 5 | $127 |
| Alkermes, Inc. | 4 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $78 |
| ABBVIE INC. | 3 | $49 |
| Supernus Pharmaceuticals, Inc. | 3 | $48 |
Products named: COBENFY, CAPLYTA, REXULTI, FANAPT, AUSTEDO XR, INGREZZA, TRINTELLIX, ABILIFY ASIMTUFII.
Industry payments across VA — which companies pay providers there.
